WHO ICTRP trial
Rituximab in the treatment of EBV infection and post-transplantation…
ChiCTR1800014960 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1800014960 |
|---|---|
| Public title | Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study |
| Scientific title | Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study |
| Primary sponsor | Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | Post-market |
| Countries | China |
| Conditions | EBV Infection |
| Interventions | Case series:Rituximab |
| Registration date | Feb 25, 2018 |
| Target size | Case series:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: